Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

1.

Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study.

Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Bladé J, Fermand JP, Hassoun H, Heffner L, Vescio RA, Liu K, Enny C, Esseltine DL, van de Velde H, Cakana A, Comenzo RL.

Blood. 2011 Jul 28;118(4):865-73. doi: 10.1182/blood-2011-02-334227. Epub 2011 May 11.

PMID:
21562045
[PubMed - indexed for MEDLINE]
Free Article
2.

Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study.

Reece DE, Sanchorawala V, Hegenbart U, Merlini G, Palladini G, Fermand JP, Vescio RA, Liu X, Elsayed YA, Cakana A, Comenzo RL; VELCADE CAN2007 Study Group.

Blood. 2009 Aug 20;114(8):1489-97. doi: 10.1182/blood-2009-02-203398. Epub 2009 Jun 4.

PMID:
19498019
[PubMed - indexed for MEDLINE]
Free Article
3.

Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis.

Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Bladé J, Fermand JP, Hassoun H, Heffner L, Kukreti V, Vescio RA, Pei L, Enny C, Esseltine DL, van de Velde H, Cakana A, Comenzo RL.

Blood. 2014 Oct 16;124(16):2498-506. doi: 10.1182/blood-2014-04-568329. Epub 2014 Sep 8.

PMID:
25202139
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects.

Dubrey SW, Reece DE, Sanchorawala V, Hegenbart U, Merlini G, Palladini G, Fermand JP, Vescio RA, Bladé J, Heffner LT, Hassoun H, Liu X, Enny C, Ramaswami P, Elsayed Y, Van De Velde H, Mortimer S, Cakana A, Comenzo RL; Velcade Can2007 Study Group.

QJM. 2011 Nov;104(11):957-70. doi: 10.1093/qjmed/hcr105. Epub 2011 Jul 13.

PMID:
21752867
[PubMed - indexed for MEDLINE]
Free Article
5.

Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma.

Gerecitano J, Portlock C, Hamlin P, Moskowitz CH, Noy A, Straus D, Schulman P, Dumitrescu O, Sarasohn D, Pappanicholaou J, Iasonos A, Zhang Z, Mo Q, Horanlli E, Rojas CN, Zelenetz AD, O'Connor OA.

Clin Cancer Res. 2011 Apr 15;17(8):2493-501. doi: 10.1158/1078-0432.CCR-10-1498. Epub 2011 Feb 23.

PMID:
21346146
[PubMed - indexed for MEDLINE]
Free Article
6.

Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.

Chen CI, Kouroukis CT, White D, Voralia M, Stadtmauer E, Stewart AK, Wright JJ, Powers J, Walsh W, Eisenhauer E; National Cancer Institute of Canada Clinical Trials Group.

J Clin Oncol. 2007 Apr 20;25(12):1570-5. Epub 2007 Mar 12.

PMID:
17353550
[PubMed - indexed for MEDLINE]
Free Article
7.

Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network.

Hainsworth JD, Spigel DR, Barton J, Farley C, Schreeder M, Hon J, Greco FA.

Cancer. 2008 Aug 15;113(4):765-71. doi: 10.1002/cncr.23606.

PMID:
18543319
[PubMed - indexed for MEDLINE]
Free Article
8.

Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma.

de Vos S, Goy A, Dakhil SR, Saleh MN, McLaughlin P, Belt R, Flowers CR, Knapp M, Hart L, Patel-Donnelly D, Glenn M, Gregory SA, Holladay C, Zhang T, Boral AL.

J Clin Oncol. 2009 Oct 20;27(30):5023-30. doi: 10.1200/JCO.2008.17.7980. Epub 2009 Sep 21.

PMID:
19770386
[PubMed - indexed for MEDLINE]
Free Article
9.

Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease.

Wechalekar AD, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD.

Haematologica. 2008 Feb;93(2):295-8. doi: 10.3324/haematol.11627.

PMID:
18245653
[PubMed - indexed for MEDLINE]
Free Article
10.

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.

Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Adams J, Kauffman M, Esseltine DL, Schenkein DP, Anderson KC.

Br J Haematol. 2004 Oct;127(2):165-72.

PMID:
15461622
[PubMed - indexed for MEDLINE]
11.

Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study.

Davis NB, Taber DA, Ansari RH, Ryan CW, George C, Vokes EE, Vogelzang NJ, Stadler WM.

J Clin Oncol. 2004 Jan 1;22(1):115-9.

PMID:
14701773
[PubMed - indexed for MEDLINE]
Free Article
12.

Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma.

Gerecitano J, Portlock C, Moskowitz C, Hamlin P, Straus D, Zelenetz AD, Zhang Z, Dumitrescu O, Sarasohn D, Lin D, Pappanicholaou J, Cortelli BM, Neylon E, Hamelers R, Wright J, O'Connor OA.

Br J Haematol. 2009 Sep;146(6):652-5. doi: 10.1111/j.1365-2141.2009.07775.x. Epub 2009 Jul 16.

PMID:
19624539
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC).

Li T, Ho L, Piperdi B, Elrafei T, Camacho FJ, Rigas JR, Perez-Soler R, Gucalp R.

Lung Cancer. 2010 Apr;68(1):89-93. doi: 10.1016/j.lungcan.2009.05.009. Epub 2009 Jun 12.

PMID:
19524318
[PubMed - indexed for MEDLINE]
14.

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Bladé J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC; Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators.

N Engl J Med. 2005 Jun 16;352(24):2487-98.

PMID:
15958804
[PubMed - indexed for MEDLINE]
Free Article
15.

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC.

N Engl J Med. 2003 Jun 26;348(26):2609-17.

PMID:
12826635
[PubMed - indexed for MEDLINE]
Free Article
16.

A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma.

Ghobrial IM, Munshi NC, Harris BN, Shi P, Porter NM, Schlossman RL, Laubach JP, Anderson KC, Desaiah D, Myrand SP, Wooldridge JE, Richardson PG, Abonour R.

Am J Hematol. 2011 Jul;86(7):573-8. doi: 10.1002/ajh.22048. Epub 2011 May 31.

PMID:
21630305
[PubMed - indexed for MEDLINE]
17.

Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up.

Berenson JR, Yang HH, Vescio RA, Nassir Y, Mapes R, Lee SP, Wilson J, Yellin O, Morrison B, Hilger J, Swift R.

Ann Hematol. 2008 Aug;87(8):623-31. doi: 10.1007/s00277-008-0501-0. Epub 2008 May 8.

PMID:
18463870
[PubMed - indexed for MEDLINE]
18.

Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone.

Kastritis E, Anagnostopoulos A, Roussou M, Toumanidis S, Pamboukas C, Migkou M, Tassidou A, Xilouri I, Delibasi S, Psimenou E, Mellou S, Terpos E, Nanas J, Dimopoulos MA.

Haematologica. 2007 Oct;92(10):1351-8.

PMID:
18024372
[PubMed - indexed for MEDLINE]
Free Article
19.

Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma.

Popat R, Oakervee H, Williams C, Cook M, Craddock C, Basu S, Singer C, Harding S, Foot N, Hallam S, Odeh L, Joel S, Cavenagh J.

Br J Haematol. 2009 Mar;144(6):887-94. doi: 10.1111/j.1365-2141.2008.07572.x. Epub 2009 Jan 12.

PMID:
19183191
[PubMed - indexed for MEDLINE]
20.

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.

Orlowski RZ, Voorhees PM, Garcia RA, Hall MD, Kudrik FJ, Allred T, Johri AR, Jones PE, Ivanova A, Van Deventer HW, Gabriel DA, Shea TC, Mitchell BS, Adams J, Esseltine DL, Trehu EG, Green M, Lehman MJ, Natoli S, Collins JM, Lindley CM, Dees EC.

Blood. 2005 Apr 15;105(8):3058-65. Epub 2004 Dec 30.

PMID:
15626743
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk